In conclusion, in this work, we identified and elucidated a novel mechanism of resistance to oHSV therapy by which oHSV therapy induces cancer–TME cell communication via NFκB-dependent IGF2 expression and secretion. This evidence concerns the gene NFKB1 and cancer.